reports
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...
- Stephane Foucaud
AUCTUS ON FRIDAY - 08/08/2025
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.30 per share: High production at Z&G. Low risk exploration drilling in Austria to start in 4Q25/1Q26 – 2Q25 net production of 303 boe/d was higher than our expectations of ~270 boe/d following a 5 well intervention programme at the Zisterdorf and Gaiselberg fields in the Vienna Basin. The programme included (1) repair of subsurface equipment, (2) clean out of a down hole sand control (3) perfor...
EOG EUROPA OIL & GAS (HOLDINGS) PLC
GTE GRAN TIERRA ENERGY
GPRK GEOPARK
EGY VAALCO ENERGY INC.
GENL GENEL ENERGY
ALVOF ALVOPETRO ENERGY LTD
PEN PANORO ENERGY ASA
SNM SHAMARAN PETROLEUM CORP.
VLE VALEURA ENERGY INC.
SQZ SERICA ENERGY
FEC FRONTERA ENERGY CORP
BP. BP P.L.C.
CNE CANACOL ENERGY LTD
KOS KOSMOS ENERGY LTD.
ORC/B ORCA EXPLORATION GROUP CL B
TAL PETROTAL (TAL)
HBR HARBOUR ENERGY PLC
ADX ADX ENERGY LTD
TNZ TENAZ ENERGY CORP
- Filipe Botelho
- Josseline Jenssen
- Lorena Reich
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises ...
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-ov...
- Josseline Jenssen
- Lorena Reich
- Stephane Foucaud
AUCTUS ON FRIDAY - 01/08/2025
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.30 per share: Operating update – Net production in Austria was 303 boe/d. The company held A$4.8 mm in cash at the end of June. Criterium Energy (CEQ CN)C; Target price of C$0.35 per share: Successful flow test at North-MGH boosts expected 2H26 gas production to 7-10 mmcf/d – The MGH-20 well in the North Mengoepeh (MGH) field tested 2.8 mmcf/d with associated oil. This is a positive surprise a...
QEC QUESTERRE ENERGY CORP.
GTE GRAN TIERRA ENERGY
RKH ROCKHOPPER EXPLORATION
OMV OMV AG
PXT PAREX RESOURCES INC.
SEI. SINTANA ENERGY
VLE VALEURA ENERGY INC.
SQZ SERICA ENERGY
BWE BW ENERGY
SEPLAT SEPLAT ENERGY PLC
SOUC SOUTHERN ENERGY CORP
PXEN PROSPEX ENERGY PLC
CEQ CRITERIUM ENERGY LTD.
NOG NOSTRUM OIL & GAS PLC
PRD PREDATOR OIL & GAS HOLDINGS PLC
ADX ADX ENERGY LTD
MCFNF MCF ENERGY LTD
SHELL ROYAL DUTCH SHELL
Myriad Genetics Announces New $200 Million Credit Facility
Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-mo...
- Filipe Botelho
- Josseline Jenssen
- Lorena Reich
Myriad Genetics to Release Second Quarter 2025 Financial Results on Au...
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conference call can be ...
Myriad Genetics Earns 2025 Great Place To Work Certification™
Myriad Genetics Earns 2025 Great Place To Work Certification™ SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work – 30 percentage points higher than the average U.S. company. “Our focus on inclusivity and caring makes this a great p...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
OXY OCCIDENTAL PETROLEUM CORPORATION
VSAT VIASAT INC.
RDWR RADWARE LTD.
MRCY MERCURY SYSTEMS INC.
GTE GRAN TIERRA ENERGY
DAR DARLING INGREDIENTS INC.
AVAV AEROVIRONMENT INC.
EFR ENERGY FUELS
NEM NEMETSCHEK SE
FSLR FIRST SOLAR INC.
SJT SAN JUAN BASIN ROYALTY TRUST
LEU CENTRUS ENERGY CORPORATION
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
SDRL SEADRILL LTD.
NEON NEONODE INC.
LHX L3HARRIS TECHNOLOGIES INC
JAN JANONE INC
MP MP MATERIALS CORP (A)
RTX RAYTHEON TECHNOLOGIES CORPORATION
APA APA CORPORATION
SHLS SHOALS TECHNOLOGIES GROUP
OVV OVINTIV INC
SBTX SILVERBACK THERAPEUTICS
CIVI CIVITAS RESOURCES INC
ASTS AST SPACEMOBILE INC
CHRD CHORD ENERGY CORPORATION
METC RAMACO RESOURCES INC.
UMAC UNUSUAL MACHS INC NEV
VG VENTURE GLOBAL INC.
OWLT OWLET INC
- Stephane Foucaud
AUCTUS ON FRIDAY - 06/06/2025
Criterium Energy (CEQ CN)C; Target price of C$0.35 per share: On track for first gas in 1Q26 – 1Q25 production of 988 boe/d had been previously reported. Criterium held ~C$1.6 mm in cash at the end of 1Q25. The company has reduced its accounts payable by ~C$3.5 mm while inventory + amounts receivable were flat vs. YE24. Operations are expected to commence at North MGH in June. Four wells were shut-in in 2014 due to high GOR. Criterium is looking to re-open some of the wells in the area. No resou...
- Felix Fischer
- Filipe Botelho
- Josseline Jenssen
- Lorena Reich
Myriad Genetics Announces Early Access to the FirstGene Multiple Prena...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will simultaneously delive...
- Felix Fischer
PBR.N PETROLEO BRASILEIRO S/A ADS
MELI MERCADOLIBRE INC.
GTE GRAN TIERRA ENERGY
GPRK GEOPARK
ARCO ARCOS DORADOS HOLDINGS INC. CLASS A
ACD ADECOAGRO S.A.
CENCOSUD CENCOSUD S.A.
VCM.B VOLCAN COMPANIA MINERA S.A.A. CLASS B
4FZ ORBIA ADVANCE CORP. SAB DE CV
PAMP PAMPA ENERGIA SA
ALSEA ALSEA S.A.B. DE C.V.
MINSURI1 MINSUR S.A.
FALABELLA FALABELLA S.A.
TGSU2 TRANSPORTADORA DE GAS DEL SUR SA CLASS B
YPFD YPF SA CLASS D
KUOB GRUPO KUO S.A.B.
ECOPETROL ECOPETROL SA
AEROMEX GRUPO AEROMEXICO
PFAVH AVIANCA HOLDINGS SA PFD
INRETC1 INRETAIL PERU
AESGENER AES GENER S.A.
TIGO SDB MILLICOM INTERNATIONAL CELLULAR SA SWEDISH DEPOSITORY RECEIPT
NEMAKA NEMAK S.A.B. DE C.V.
CEXA CEMEX SAB DE CV (ADR)
TUPY3 TUPY S/A ORD
UGPA3 ULTRAPAR PARTICIPACOES S.A.
USIM5 USINAS SIDERURGICAS DE MINAS GERAIS PREF A
NATU3 NATURA & CO HOLDING SA
LTM LATAM AIRLINES GROUP SA
FEC FRONTERA ENERGY CORP
NEXA NEXA RESOURCES S.A.
RAIL3 RUMO SA
KALLPA KALLPA
CSNA3 COMPANHIA SIDERURGICA NACIONAL
VALE3 VALE S.A.
KLBN3 KLABIN SA
SUZANO SUZANO
UNIGEL UNIGEL
AMBP3 BZ AMBIPAR PARTICIPACOES E EMPR
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of ...
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRD SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the Na...
Myriad Genetics Highlights New Research Advancements and Oncology Inno...
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the . Myriad will also highlight how its comprehensive portfolio of genetic and tum...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healt...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Liv...
Myriad Genetics Announces RiskScore Study Published in JCO Precision O...
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integ...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates ...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, ben...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.